Charles River Laboratories Intl. Inc vs Southwest Airlines Co — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Southwest Airlines Co trades at $41.03 (market cap $20.23B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.74% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Southwest Airlines Co for 65 Days on average.
| CRL | LUV | |
|---|---|---|
Market Cap | $14.23B | $20.23B |
Volume | 1,176,885 | 14,560,422 |
Sector | Health | Industrials |
52-Week High | $310.77 | $54.80 |
52-Week Low | $149.93 | $29.67 |
Typical Hold Time | 33 Days | 65 Days |
Enterprise Value | $17.06B | $23.33B |
Dividend Yield | — | 1.74% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Southwest Airlines (LUV) trades at $41.72, down 1.72% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates improving fundamentals with Q2 2026 EPS beating expectations at $0.94 versus $0.51 expected, while revenue growth continues from $28.06B in 2025 to projected $30.1B in 2026. Recent corporate developments include upcoming Q3 2026 earnings release on October 21 and successful commercial transformation initiatives driving revenue growth.
LUV presents a compelling value opportunity with attractive valuation metrics (P/S 0.72, EV/EBITDA 8.4) and analyst consensus target of $49.61 offering 19% upside. However, investors face risks from volatile fuel costs, competitive pressures in the airline industry, and inconsistent earnings performance as seen in the Q1 2026 miss. The stock's transformation into a merchandised airline with new revenue streams provides growth catalysts but requires monitoring of execution risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →